Frederick, MD – According to filings with the U.S. Securities and Exchange Commission, Veralox Therapeutics is raising $22,750,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jeffrey Strovel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Veralox Therapeutics
VERALOX Therapeutics Inc. is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs based on advanced understanding of the role of 12-lipoxygenase (12-LOX) in the onset and development of many serious diseases and conditions. The companys lead candidate, VLX-1005, is in development for the treatment of patients with heparin-induced thrombocytopenia (HIT). Second generation therapeutic products are under development for type 1 diabetes and other immune-mediated and inflammatory diseases.

To learn more about Veralox Therapeutics, visit http://www.veraloxtx.com/

Contact:
Jeffrey Strovel, Chief Executive Officer
301-360-3502
https://www.linkedin.com/in/jeffrey-strovel-634764/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved